KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now has a market cap of close to $8 billion.

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

A total of nearly 137 million adults, representing more than half of all U.S. adults, are eligible for semaglutide therapy. This ...

Drug manufacturers have increased their production, and some such as Novo Nordisk have asked the FDA to ban further production of compounded versions of their drugs. If that happens, Lavin says many ...

US health officials report 1st case of new form of mpox in a traveler You will likely see compounded drugs marketed as an ...

Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June.

The Ipsos survey of 1,078 adults found 24% of people would use weight-loss jabs if they were provided for free by the health ...